Foley Partner David Rosen was quoted in an article that appeared in Bloomberg News on October 27, 2011 titled “FDA tightens standards to prove generics can be swapped.” Rosen discusses in-progress FDA guidelines that will impose tighter standards for generic drug makers. He states that the guidelines will potentially require companies conducting generic equivalence studies to recruit nearly twice as many people for testing, adding that a new equivalency study would require several months to test generic products against the original versions.
People
Related News
12 May 2025
In the News
Judith Waltz Comments on Provider Settlement After Self-Disclosure
Foley & Lardner LLP partner Judith Waltz commented on a recent settlement by a provider with the U.S. Department of Health and Human Services Office of Inspector General (OIG) in the Report on Medicare Compliance article, "After Self-Disclosure, Provider Settles Case Over Failure to Report, Return Overpayments."
12 May 2025
In the News
Foley's Digital Infrastructure Arrivals Featured Across Legal Press
Foley & Lardner LLP partners Daniel Farris and Joe McClendon are featured in legal press for their arrival to the firm.
07 May 2025
In the News
Foley Attorneys Featured in Q&A on CPSC Oversight of Cosmetics Industry
Foley & Lardner LLP attorneys Erik Swanholt, Kristin McGaver, and Mikaela Mitchum are featured in a Cosmetics Design Q&A on what industry brands need to know regarding oversight from the U.S. Consumer Product Safety Commission.